BioSpace News Archive

Countless microorganisms collectively thriving in and on the human body are together called as human microbiome.

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce the publication of a five year programme of work undertaken by the CANCER-ID Consortium to establish the performance and technical capabilities of five circulating tumour cell isolation platforms, in which key advantages of the Parsortix® system were identified.

During January 2021, the registered number of shares and votes in Moberg Pharma AB has increased due to the completion of the previously announced rights issue, and the final conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.

DaVita Inc., announced that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 11, 2021, at 5:00 p.m. Eastern Time.

AIM ImmunoTech Inc. announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research for the proposed AMP-COV-100 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, a critical step in the company’s ongoing efforts to develop Ampligen as a COVID-19 treatment.

Revenue in the fourth quarter of 2020 increased 22 percent, driven by volume growth of 24 percent. Excluding bamlanivimab revenue of $871 million, fourth-quarter 2020 revenue grew 7 percent.

Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct offering of an aggregate of 21,097,046 shares of common stock at a purchase price of $2.37 per share.

Vivos Therapeutics, Inc. (“Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA), today announced that the Company has established a Clinical Advisory Board

Thermo Fisher Scientific Inc., (NYSE:TMO), the world leader in serving science, was recognized as a “Best Place to Work for LGBTQ Equality” for the sixth consecutive year.